ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other nicotinamide adenine dinucleotide (NAD) precursors. This newly granted continuation patent reinforces U.S. Patent No. 11,242,364, which was just granted to ChromaDex on February 8, 2022 (full press release here). ChromaDex currently owns and licenses a robust patent portfolio of over 40 granted patents relating to Niagen® (patented NR) and other precursors of NAD, a molecule at the forefront of the burgeoning healthy aging category. Niagen® is the sole active ingredient in ChromaDex’s flagship product, Tru Niagen®.

“Awareness around the importance of NAD in aging continues to grow, and the market for novel NAD precursors, like NR, continues to expand,” said Aron Erickson, ChromaDex Vice President of Research & Development. “This patent adds further protection of a novel method of making NR chloride to our portfolio. I am honored to have led a team on the development of this important patent.”

This new patent, U.S. Patent No. 11,274,117, relates to a novel method of making nicotinamide riboside (NR) chloride salt. Both newly announced patents allow ChromaDex to protect the manufacturing process of NR Chloride and other new NR salt forms, which can be leveraged in future innovations. Like U.S. Patent No. 11,242,364, U.S. Patent No. 11,274,117 will expire Nov. 10, 2037.

U.S. Patent No. 11,274,117 is part of the patent family titled “Efficient and Scalable Syntheses of Nicotinoyl Ribosides and Reduced Nicotinoyl Ribosides, Modified Derivatives Thereof, Phosphorylated Analogs Thereof, Adenylyl Dinucleotide Conjugates Thereof, and Novel Crystalline Forms Thereof”.

For additional information on ChromaDex, please visit www.chromadex.com.

About ChromaDex

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen^®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to ChromaDex’s intellectual property position and protection provided for new salt forms which can be leveraged in future innovations. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.